About: Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 17 March 2020

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2020 (fr) artículu científicu espublizáu en marzu de 2020 (ast) scientific article published on 17 March 2020 (en) artykuł naukowy opublikowany 17 marca 2020 (pl) наукова стаття, опублікована 17 березня 2020 (uk)
publication date	wds:Q90671936-3A7611BA-D4C5-42CF-A5BF-3E2A34C793AC
publication date	2020-03-17 00:00:00Z (xsd:dateTime)
cites work	wds:Q90671936-056CB206-F35A-435D-AB90-40790DF472CE wds:Q90671936-0CC9EE2F-AEF8-47F7-8217-85DABB1B443F wds:Q90671936-0DC01F00-C0B7-416B-8D93-0C6D98C25536 wds:Q90671936-2996D0B1-2E85-4136-982F-20AF24795A9C wds:Q90671936-2BCBDF2E-F762-4AFC-9EE8-643ED4BC5D42 wds:Q90671936-57B6FD19-2799-4109-AC64-1186ECB86B9B wds:Q90671936-590FE48C-69FD-4BC3-93A1-E7343744AFD3 wds:Q90671936-5CC97881-5925-40D7-9C24-C7B32529434F wds:Q90671936-73FAFE47-82F1-46C2-A534-B13EF9D18AEF wds:Q90671936-7781645B-BA09-4E39-B897-FAEE80083CEC wds:Q90671936-7EA75BF9-CF6A-4C6C-B39F-A6DDE1F0DAE5 wds:Q90671936-80744A22-D7E5-48FB-AE44-78D94FFFDB23 wds:Q90671936-8D6BD5C2-C618-49BA-97B3-4A844A641ECF wds:Q90671936-9393A729-2C53-403E-9724-2C2CD5208B7F wds:Q90671936-A0191557-F6C8-4083-A33D-A74266108530 wds:Q90671936-B05B55A3-9D02-4474-B174-48FF2A761480 wds:Q90671936-C1A2516D-0953-46D2-BC45-4794994F1CF5 wds:Q90671936-C322340D-2F9B-4807-9718-C0514380DF72 wds:Q90671936-CB4231D4-D2CD-4222-B2D3-05026016D864 wds:Q90671936-D36058C4-CA17-4E5C-9E63-22C25760413F wds:Q90671936-DB32BB1D-C5DF-494F-8F83-37BDDE5D83D7 wds:Q90671936-EA4225D3-A2B1-4B6F-B480-925C150ED65C wds:Q90671936-F05C8487-0DFF-4AFE-86C4-86C01C05C14B
cites work	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain EGFR mutation and resistance of non-small-cell lung cancer to gefitinib Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
author name string	wds:Q90671936-097CEB18-C6E5-4AC9-B12A-23A0BFC37EF7 wds:Q90671936-0CF1BD21-2067-49AE-822B-D52800DBECCF wds:Q90671936-0E0EB64B-AFDF-495E-95B0-B20630346E4D wds:Q90671936-1F40A67D-8D2E-4BBD-A2C4-70DFA9C9D10C wds:Q90671936-3EEB0197-CE56-4A16-8E94-492D4CB068CA wds:Q90671936-612A1906-B7B8-4CA5-BB14-6E85E36D29B7 wds:Q90671936-693B00A4-9358-4364-9D4C-15CF46F07E04 wds:Q90671936-6CF1AF04-73DF-4A2D-9023-3C522306074D wds:Q90671936-A14C57F4-8F1D-433A-B574-10EFDDDFF4C0 wds:Q90671936-A24D133F-DB19-42B1-9545-25D053E4BB1B wds:Q90671936-A46C5418-0037-454C-B248-DBC945212DDD wds:Q90671936-AC1CF910-C8E4-4976-A688-C9C14D872402 wds:Q90671936-DCBC4441-F7E6-456F-902E-0CCD3010A65A wds:Q90671936-E84DCCC1-3B20-4C52-8623-8565D23D0D38 wds:Q90671936-FB47C82F-38A4-425D-8AF2-1BBDE8EA8C1E
author name string	Antonio Marchetti Fiamma Buttitta Lara Felicioni Luciana Irtelli Davide Brocco Giovanni Cianci Alessandra Di Paolo Alessia Di Lorito Donatella Traisci Francesca Fabbri Francesco Malorgio Nicola D'Ostilio Pasquale Assalone Pietro Di Marino Sonia Di Felice
rdfs:label	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (en) Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (nl)
skos:prefLabel	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (en) Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (nl)
name	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (en) Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (nl)
author	wds:Q90671936-0370FB8D-599B-41EF-AFF5-C81477D65E3B wds:Q90671936-D0E6D465-E588-4282-B798-5CF515BFE92A
author	Michele De Tursi Alessio Cortellini
title	wds:Q90671936-C0C907F9-0F1B-4944-BD4A-9AA8FD696D79
title	Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment (en)
page(s)	wds:Q90671936-1513ADA1-FCBC-46F5-BA77-6607A1602904
page(s)	982-991
instance of	wds:Q90671936-66F23DA0-3591-4C63-9091-4327C8B925FD

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software